DNA NYSE
Ginkgo Bioworks Holdings, Inc.
1W: +2.8%
1M: -4.4%
3M: -12.5%
YTD: -7.2%
1Y: +1.0%
3Y: -83.9%
5Y: -98.0%
$8.41
+0.33 (+4.08%)
Weekly Expected Move ±14.7%
$5
$7
$8
$9
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$170M
-25.1% ▼
5Y CAGR: +17.3%
Gross Profit
$139M
-26.5% ▼
5Y CAGR: +17.8%
Operating Income
-$315M
+43.7% ▲
Net Income
-$313M
+42.8% ▲
EPS (Diluted)
$-5.64
+46.5% ▲
EBITDA
-$255M
+47.4% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $314M | $478M | $251M | $227M | $170M |
| YoY Growth | +309.4% | +52.2% | -47.4% | -9.7% | -25.1% |
| Cost of Revenue | $130M | $204M | $54M | $39M | $32M |
| Gross Profit | $184M | $273M | $197M | $188M | $139M |
| Gross Margin | 58.7% | 57.3% | 78.5% | 83.0% | 81.5% |
| R&D Expenses | $1.1B | $1.1B | $581M | $424M | $244M |
| SG&A Expenses | $863M | $1.4B | $385M | $246M | $183M |
| Operating Expenses | $2.0B | $2.5B | $1.1B | $748M | $454M |
| Operating Income | -$1.8B | -$2.2B | -$864M | -$560M | -$315M |
| Operating Margin | -582.6% | -462.4% | -343.8% | -246.5% | -185.3% |
| Interest Expense | $2M | $106K | $93K | $94K | $0 |
| Income Before Tax | -$1.8B | -$2.1B | -$893M | -$548M | -$314M |
| Tax Expense | -$1M | -$15M | -$71K | -$479K | -$837K |
| Net Income | -$1.8B | -$2.1B | -$893M | -$547M | -$313M |
| Net Margin | -583.1% | -440.6% | -355.1% | -240.9% | -183.8% |
| EPS (Diluted) | $-55.53 | $-50.20 | $-18.40 | $-10.54 | $-5.64 |
| EBITDA | -$1.8B | -$2.1B | -$821M | -$484M | -$255M |
| Shares Outstanding | 34M | 42M | 49M | 52M | 55M |